Although substantial epidemiological studies have failed to find a correlation between cholesterol levels and stroke, clinical trials have shown that HMG-CoA reductase inhibitors (or statins, the most potent hypocholesterolemic drugs available) greatly reduce the incidence of stroke. These clinical observations have opened the way to a number of studies of the non—cholesterol-dependent (or pleiotropic) effects in animal models of stroke, indicating that the neuroprotection is attributable to multiple activities. One of the main protective mechanisms elicited by statin administration is the increase in nitric oxide bioavailability that regulates cerebral perfusion and improves endothelial function, but others include antioxidant properties, the inhibition of inflammatory responses, immunomodulatory actions, the regulation of progenitor cells, and the stabilization of atherosclerotic plaques. Many of these effects are due to the inhibited synthesis of isoprenoid intermediates, which serve as lipid attachments for a variety of intracellular signaling molecules. This article describes the mechanisms involved in the neuroprotective effects of statins. NEUROSCIENTIST 13(3):208—213, 2007.
Asahi M., Huang Z., Thomas S., Yoshimura S., Sumii T., Mori T., and others.2005 . Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J Cereb Blood Flow Metab25:722—9.
2.
Balduini W., Mazzoni E., Carloni S., De Simoni MG, Perego C., Sironi L., and others. 2003. Prophylactic but not delayed administration of simvastatin protects against long-lasting cognitive and morphological consequences of neonatal hypoxic-ischemic brain injury, reduces interleukin-1beta and tumor necrosis factor alpha mRNA, and does not affect endothelial nitric oxide synthase expression. Stroke34:2007—12.
3.
Barone FC, Feuerstein GZ1999. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab19:819—34.
4.
Boutin H., LeFeuvre RA, Horai R., Asano M., Ywakura Y., Rothwell NJ2001. Role of IL-1alpha and IL-1beta in ischemic brain damage . J Neurosci21:5528—34.
5.
Carloni S., Mazzoni E., Cimino M., De Simoni MG, Perego C., Scopa C., and others. 2006. Simvastatin reduces caspase-3 activation and inflammatory markers induced by hypoxia-ischemia in the newborn rat. Neurobiol Dis21:119—26.
6.
Chan PH2004. Mitochondria and neuronal death/survival signaling. Neurochem Res29:1943—9.
7.
Danton GH, Dietrich WD2003. Inflammatory mechanisms after ischemia and stroke. J NeuropatolExp Neurol62:127—36.
8.
Dimmeler S., Aicher A., Vasa M., Mildner-Rihm C., Adler K., Tiemann M., and others.2001 . HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/Akt pathway. J Clin Invest108:391—7.
9.
Dirnagl U., Iadecola C., Moskowitz MA1999. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci22:391—7.
10.
Elkind MS2006. Inflammation, atherosclerosis, and stroke. Neurologist12:140—8.
11.
Endres M.2005. Statins and stroke. J Cereb Blood Flow Metab25:1093—110.
12.
Endres M., Laufs U., Huang Z., Nakamura T., Huang PL, Moskowitz MA, and others.1998 . Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA95:8880—5.
13.
Endres M., Laufs U., Liao JK, Moskowitz MA2004. Targeting eNOS for stroke protection. Trends Neurosci27:283—9.
Gorlach A., Brandes RP, Nguyen K., Amidi M., Deghani F., Busse R.2000. A gp91phox-containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res87:26—32.
16.
Iadecola C., Alexander M.2001. Cerebral ischemia and inflammation. Curr Opin Neurol14:89—94.
17.
Iadecola C., Niwa K., Nogawa S., Zhao X., Nagayama M., Araki E., and others.2001 . Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA98:1294—9.
18.
Kureishi J., Luo Z., Shiojima I., Bialik A., Fulton D., Leer DJ, and others.2000 . The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals . Nat Med6:1004—10.
19.
Laufs U.2003. Beyond lipid-lowering: effects of statin on endothelial nitric oxide. Eur J Pharmacol58:719—31.
20.
Le QuanSang KH, Levenson J., Megnien JL, Simon A., Devinck MA1995. Platelet cytosolic Ca2+ and membrane dynamics in patients with primary hypercholesterolemia: effects of pravastatin. Arterioscler Thromb Vasc Biol15:759—64.
21.
Liao JK, Laufs U.2005. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol45:89—118.
22.
Llevadot J., Murasawa S., Kureishi Y., Uchida S., Masuda H., Kawamoto A., and others.2001 . HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest108:399—405.
23.
Lo EG, Dalkara T., Moskowitz MA2003. Mechanisms, challenges and opportunities in stroke . Nat Rev Neurosci4:399—15.
24.
Mergenthaler P., Dirnagl U., Meisel A.2004. Pathophysiology of stroke: lessons from animal models . Metab Brain Dis19:151—67.
25.
Moro MA, Cardenas A., Hurtado O., Leza JC, Lizasoain I.2004. Role of nitric oxide after brain ischaemia. Cell Calcium36:265—75.
26.
Orrenius S., Zhivotovsky B., Nicotera P.2003. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol4:552—65.
27.
Pahan K., Sheikh FG, Namboodiri AM, Singh I.1997. Lovastatin and ophenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia and macrophages. J Clin Invest100:2671—9.
Sironi L., Banfi C., Brioschi M., Gelosa P., Guerrini U., Nobili E., and others.2006 . Activation of NF-kB and ERK1/2 after permanent focal ischemia is abolished by simvastatin treatment. Neurobiol Dis22:445—51.
30.
Sironi L., Cimino M., Guerrini U., Calvio AM, Lodetti B., Asdente M., and others.2003 . Treatment with statin after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler Thromb Vasc Biol23:322—7.
31.
Turley KR, Toledo-Pereyra Lh, Kothari RU2005. Molecular mechanisms in the pathogenesis and treatment of acute ischemic stroke. J Invest Sur18:207—18.
32.
Vaughan CJ, Delanty N.1999. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke30:1969—73.
33.
Vaughan CJ, Gotto AM, Basson CT2000. The evolving role of statins in the management of atherosclerosis . J Am Coll Cardiol35:1—10.
34.
Wagner AK, Kohler T., Ruckschloss U., Just I., Hecker M.2000. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol20:61—9.
35.
Wassmann S., Laufs U., Baumer AT, Muller K., Konkol C., Sauer H., and others.2001 . Inhibition of geranylgeranylation reduces angiotensin II—mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol59:646—54.
36.
Werner N., Priller J., Laufs U., Endres M., Bohm M., Dirnagl U., and others.2002 . Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition. Arterioscler Thromb Vasc Biol22:1567—72.
37.
Yamada M., Huang Z., Dalkara T., Endres M., Laufs U., Waeber C., and others.2000 . Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J Cereb Blood Flow Metab20:709—17.
38.
Zhang F., Yin W., Chen J.2004. Apoptosis in cerebral ischemia: executional and regulatory signaling mechanisms. Neurol Res26: 835—45.
39.
Zhang RL, Zhang ZG, Chopp M.2005. Neurogenesis in the adult ischemic brain: generation, migration, survival and restorative therapy. Neuroscientist11:408—16.
